These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16483183)

  • 1. Intense 18-fluorodeoxyglucose uptake by the thymus on PET scan does not necessarily herald recurrence of thyroid carcinoma.
    Godart V; Weynand B; Coche E; De Nayer P; Daumerie C
    J Endocrinol Invest; 2005 Dec; 28(11):1024-8. PubMed ID: 16483183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
    Muros MA; Llamas-Elvira JM; Ramírez-Navarro A; Gómez MJ; Rodríguez-Fernández A; Muros T; López de la Torre M; Becerra A; Carreras JL
    Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
    Hung MC; Wu HS; Kao CH; Chen WK; Changlai SP
    Endocr Res; 2003 May; 29(2):169-75. PubMed ID: 12856803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal threshold of stimulated serum thyroglobulin level for
    Chai H; Zhang H; Yu YL; Gao YC
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):429-432. PubMed ID: 28585147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
    Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
    Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
    Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan].
    Sanz Viedma S; Borrego Dorado I; Rodríguez Rodríguez JR; Navarro González E; Vázquez Albertino R; Fernández López R; Agudo Martínez A
    Rev Esp Med Nucl; 2011; 30(2):77-82. PubMed ID: 21334773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
    Moog F; Linke R; Manthey N; Tiling R; Knesewitsch P; Tatsch K; Hahn K
    J Nucl Med; 2000 Dec; 41(12):1989-95. PubMed ID: 11138683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
    Ong SC; Ng DC; Sundram FX
    Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
    Kim WG; Ryu JS; Kim EY; Lee JH; Baek JH; Yoon JH; Hong SJ; Kim ES; Kim TY; Kim WB; Shong YK
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1169-73. PubMed ID: 20080852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography.
    Wu YJ; Wu HS; Yen RF; Shen YY; Kao CH
    Anticancer Res; 2003; 23(3C):2973-6. PubMed ID: 12926147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.